The incidence proportion of bone metastases was highest among patients with the HR‐positive HER2‐negative and HR‐positive HER2‐positive subtypes, which are in accordance with other publications describing the patterns of metastatic breast cancer.11, 12, 36 The multivariable logistic regression indicated that patients with the HR‐positive HER2‐negative subtype had significantly greater odds of having bone metastases at diagnosis than patients with other subtypes, whether among the entire cohort or within the subset with metastatic disease. This evidence concerns the gene ERBB2 and metastatic neoplasm.